Novartis vets get $35M to pluck one of the pharma giant’s abandoned drugs off the shelf and put it back into a clinical trial
Back in 2006, Novartis execs scooped up rights to Kyorin’s immunosuppressant drug program for KRP-203, an S1P drug that the pharma giant initially thought had …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
